<DOC>
	<DOCNO>NCT02513004</DOCNO>
	<brief_summary>This study design test hypothesis onset antiplatelet effect 90mg-first-dose ticagrelor rapid great 300mg-loading-dose clopidogrel evaluate P2Y12 reaction unit measure Verify NowTM P2Y12 assay 1 hour patient undergoing one-stop Hybrid coronary revascularization ( HCR ) .</brief_summary>
	<brief_title>Evaluation Antiplatelet Effects Safety Intraoperative Administration Ticagrelor Versus Clopidogrel</brief_title>
	<detailed_description>This single-center , randomize , active-controlled , open-label , prospective study , study design test hypothesis onset antiplatelet effect 90mg-first-dose ticagrelor rapid great 300mg-loading-dose clopidogrel evaluate P2Y12 reaction unit ( PRU ) measure Verify NowTM P2Y12 assay 1 hour patient undergo one-stop HCR . The first dose study drug ( ticagrelor 90mg clopidogrel 300 mg ) administer powder via nasogastric tube conﬁrmation leave internal mammal artery leave anterior descend coronary antery ( LIMA-LAD ) graft patency HCR procedure . Approximately 60 patient enrol study . Patients randomize equally ( ratio 1:1 ) two treatment arm study . The anticipated duration study approximately 15 month , include anticipated enrolment period 12 month follow-up period 3months .</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . A patient consider ethnic Chinese 3 . 80years &gt; age &gt; 18years , male female 4 . Patient willing perform HCR follow condition : Multivessel coronary artery disease unfavorable leave anterior descend coronary artery ( LAD ) percutaneous coronary intervetion ( PCI ) ( i.e. , chronic total occlusion , excessive tortuosity , severely diffuse lesion ) , unprotected leave main coronary artery disease , nonLAD lesion technically feasible PCI drugeluting stent ( DES ) .Limitations traditional coronary artery bypass graft ( CABG ) , preexist organ dysfunction , heavily calciﬁed proximal aorta , lack suitable graft conduit 1 . Involvement plan and/or conduct study 2 . Previous enrolment randomization present study 3 . Participation another clinical study investigational product last 30 day 4 . Contraindication reason clopidogrel ticagrelor administer ( eg , hypersensitivity , active bleeding , moderate severe liver disease , history previous intracranial bleed , GI bleed within past 6 month , major surgery within 30 day ) 5 . With coagulation disorder 6 . With uric acid nephropathy 7 . History intolerance allergy acetylsalicylic acid ( ASA ) clopidogrel ticagrelor 8 . Patient coronary artery bypass graft ( CABG ) history . 9. leave subclavian artery LIMA stenosis 10. bury intramyocardial LAD 11. need concomitant operation ( e.g. , valve repair replacement ) 12. overt congestive heart failure 13 . Unsuccessful LIMALAD graft 14. hemodynamic instability 15. condition render PCI unsuitable ( e.g. , fresh thrombus , coronary vessel diameter &lt; 1.5 mm ) 16 . Platelet count less 100*10^9/L 17 . Haemoglobin ( Hb ) level le 110g/L 18 . White blood cell count less 4*10^12/L 19 . Recent ( within 30 day dose ) blood donation 20 . Fibrinolytic therapy 24 hour prior randomisation , plan fibrinolytic treatment follow randomisation ( eg , STsegment elevation myocardial infarction pulmonary embolism ) 21 . P2Y12 receptor inhibitor therapy 7 day HCR surgery . 22 . Nonselective nonsteroidal antiinflammatory drug ( NSAIDs ) prostacyclins ( PGI2 ) therapy stop 23 . Increased risk bradycardic event ( eg , pacemaker know sick sinus syndrome , second degree atrioventricular block , third degree atrioventricular block previous document syncope suspect due bradycardia ) . 24 . Concomitant oral intravenous therapy ( see example ) strong CYP3A inhibitor , CYP3A substrates narrow therapeutic index , strong CYP3A inducer within 14 day study treatment stop course study . Strong inhibitor : ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atanazavir , 1 litre daily grapefruit juice . Substrates narrow therapeutic index : cyclosporine , quinidine . Strong inducer : rifampin/rifampicin , phenytoin , carbamazepine . The sponsor consult enrolment concomitant medicine suspect undergoing strong drugdrug interaction 25 . Any condition opinion investigator , may either put patient risk influence result study ( e.g. , cardiogenic shock active cancer ) 26 . Moderate severe renal disease ; 27 . Moderate severe chronic lung disease asthma ; 28 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>